Literature DB >> 24081735

Identification of AP2S1 mutation and effects of low calcium formula in an infant with hypercalcemia and hypercalciuria.

Yasuko Fujisawa1, Rie Yamaguchi, Eiichirou Satake, Konosuke Ohtaka, Toshiki Nakanishi, Keiichi Ozono, Tsutomu Ogata.   

Abstract

CONTEXT: Although AP2S1 has recently been shown to be a causative gene for familial hypocalciuric hypercalcemia type 3 (FHH3), knowledge about FHH3 remains poor.
OBJECTIVE: Our objective was to report AP2S1 mutation and effects of low calcium formula in a patient with hypercalcemia and hypercalciuria. PATIENT: This Japanese female infant was found to have hypercalcemia by a routine laboratory test for poor weight gain on breast feeding. At 49 days of age, serum calcium (adjusted by Payne's formula) was 13.1 mg/dL, intact PTH 27 pg/mL, and urinary calcium-to-creatinine ratio 1.29 mg/mg. There was no evidence for hyperparathyroidism, PTHrP-producing neoplasm, and vitamin D excess. These data, except for hypercalciuria, appeared to be consistent with defective calcium-sensing receptor-mediated signaling. With use of low calcium formula containing 2.6 mg/dL of calcium, she showed catch-up growth, and serum calcium was decreased, as was urinary calcium-to-creatinine ratio. Furthermore, feeding with a mixture of low calcium formula and standard formula with a 2:1 ratio maintained serum calcium ∼12 mg/dL without markedly increasing serum PTH.
RESULTS: Although no pathologic mutation was detected in CASR or GNA11, a presumably de novo heterozygous mutation (p.Arg15Leu), a previously reported causative mutation for FHH3, was identified in AP2S1 of this patient.
CONCLUSIONS: The results imply that lack of hypocalciuria does not necessarily argue against the presence of AP2S1 mutations. The early infantile age of this patient would have played a certain role in the occurrence of hypercalciuria, and low calcium formula is worth attempting in infants with FHH.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24081735     DOI: 10.1210/jc.2013-2571

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  Ruling in a suspect: the role of AP2S1 mutations in familial hypocalciuric hypercalcemia type 3.

Authors:  Geoffrey N Hendy; David E C Cole
Journal:  J Clin Endocrinol Metab       Date:  2013-12       Impact factor: 5.958

2.  Neonatal Severe Hyperparathyroidism: Novel Insights From Calcium, PTH, and the CASR Gene.

Authors:  Stephen J Marx; Ninet Sinaii
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

Review 3.  International Union of Basic and Clinical Pharmacology. CVIII. Calcium-Sensing Receptor Nomenclature, Pharmacology, and Function.

Authors:  Katie Leach; Fadil M Hannan; Tracy M Josephs; Andrew N Keller; Thor C Møller; Donald T Ward; Enikö Kallay; Rebecca S Mason; Rajesh V Thakker; Daniela Riccardi; Arthur D Conigrave; Hans Bräuner-Osborne
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

4.  Stepwise CaSR, AP2S1, and GNA11 sequencing in patients with suspected familial hypocalciuric hypercalcemia.

Authors:  Auryan Szalat; Shoshana Shpitzen; Anat Tsur; Ilana Zalmon Koren; Shmuel Shilo; Liana Tripto-Shkolnik; Ronen Durst; Eran Leitersdorf; Vardiella Meiner
Journal:  Endocrine       Date:  2017-02-07       Impact factor: 3.633

Review 5.  Therapeutic Opportunities of Targeting Allosteric Binding Sites on the Calcium-Sensing Receptor.

Authors:  Jiayin Diao; Aaron DeBono; Tracy M Josephs; Jane E Bourke; Ben Capuano; Karen J Gregory; Katie Leach
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-08

6.  A G-protein Subunit-α11 Loss-of-Function Mutation, Thr54Met, Causes Familial Hypocalciuric Hypercalcemia Type 2 (FHH2).

Authors:  Caroline M Gorvin; Treena Cranston; Fadil M Hannan; Nigel Rust; Asjid Qureshi; M Andrew Nesbit; Rajesh V Thakker
Journal:  J Bone Miner Res       Date:  2016-02-06       Impact factor: 6.741

Review 7.  Disorders of the calcium-sensing receptor and partner proteins: insights into the molecular basis of calcium homeostasis.

Authors:  Fadil M Hannan; Valerie N Babinsky; Rajesh V Thakker
Journal:  J Mol Endocrinol       Date:  2016-10       Impact factor: 5.098

8.  Multiple endocrine neoplasia phenocopy revealed as a co-occurring neuroendocrine tumor and familial hypocalciuric hypercalcemia type 3.

Authors:  Silje Hovden; Marie Louise Jespersen; Peter H Nissen; Per Løgstrup Poulsen; Lars Rolighed; Søren A Ladefoged; Lars Rejnmark
Journal:  Clin Case Rep       Date:  2016-08-18

9.  Adaptor protein-2 sigma subunit mutations causing familial hypocalciuric hypercalcaemia type 3 (FHH3) demonstrate genotype-phenotype correlations, codon bias and dominant-negative effects.

Authors:  Fadil M Hannan; Sarah A Howles; Angela Rogers; Treena Cranston; Caroline M Gorvin; Valerie N Babinsky; Anita A Reed; Clare E Thakker; Detlef Bockenhauer; Rosalind S Brown; John M Connell; Jacqueline Cook; Ken Darzy; Sarah Ehtisham; Una Graham; Tony Hulse; Steven J Hunter; Louise Izatt; Dhavendra Kumar; Malachi J McKenna; John A McKnight; Patrick J Morrison; M Zulf Mughal; Domhnall O'Halloran; Simon H Pearce; Mary E Porteous; Mushtaqur Rahman; Tristan Richardson; Robert Robinson; Isabelle Scheers; Haroon Siddique; William G Van't Hoff; Timothy Wang; Michael P Whyte; M Andrew Nesbit; Rajesh V Thakker
Journal:  Hum Mol Genet       Date:  2015-06-16       Impact factor: 6.150

Review 10.  The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases.

Authors:  Fadil M Hannan; Enikö Kallay; Wenhan Chang; Maria Luisa Brandi; Rajesh V Thakker
Journal:  Nat Rev Endocrinol       Date:  2018-12       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.